- Report
- January 2025
- 157 Pages
Global
From €3798EUR$4,150USD£3,300GBP
- Report
- April 2025
- 50 Pages
Global
From €2425EUR$2,650USD£2,107GBP
- Report
- October 2024
- 189 Pages
Global
From €3244EUR$3,545USD£2,819GBP
€3605EUR$3,939USD£3,132GBP
- Report
- May 2024
- 128 Pages
Global
From €5947EUR$6,499USD£5,167GBP
- Report
- April 2025
- 93 Pages
Global
From €5125EUR$5,600USD£4,453GBP
- Report
- July 2024
- 138 Pages
Global
From €2744EUR$2,999USD£2,385GBP
- Report
- March 2022
- 300 Pages
Global
From €4576EUR$5,000USD£3,976GBP
- Report
- April 2020
- 115 Pages
Global
From €3349EUR$3,660USD£2,910GBP
Tranexamic acid is a hematological drug used to treat and prevent excessive bleeding. It is a synthetic derivative of the amino acid lysine and is used to reduce the breakdown of blood clots. It is commonly used to treat heavy menstrual bleeding, nosebleeds, and bleeding after surgery or childbirth. It is also used to reduce the risk of bleeding in people with hemophilia and other bleeding disorders. Tranexamic acid is available in both oral and intravenous forms.
Tranexamic acid is a widely used hematological drug, with a variety of applications in the treatment and prevention of excessive bleeding. It is used in a range of medical settings, from emergency care to long-term management of bleeding disorders.
Companies in the tranexamic market include Pfizer, Sanofi, Novartis, Bayer, and Teva Pharmaceuticals. Show Less Read more